Scrip Regulatory Affairs
EU Drug and Medtech Regulation: a Deliberate Shift in Power Away from Member States
August 2013
In the field of pharmaceutical and medical device regulation in the EU, power is increasingly moving from member states to Brussels. This is largely a good thing for the life sciences industry as it will make Europe more competitive internationally.
This article was published in the August 2013 issue of Scrip Regulatory Affairs.
Capabilities
Suggested News & Insights
EU Pharma Package: Sharp New Tools With Limited ProtectionsDecember 18, 2025EU Biotech Act: EU Proposes First Set of Rules to Facilitate Biopharmaceutical CompetitivenessThursday, December 18, 2025First Chair Trial and Leading Product Liability Lawyer Paul Boehm Joins Sidley as Partner in D.C. to Expand Product Liability and Mass Torts Litigation PracticeDecember 18, 2025Sidley Represents Changchun GeneScience (GenSci) Pharmaceuticals in Its Strategic Licensing Agreement With Yarrow Bioscience for First-in-Class Autoimmune Thyroid Disease TherapyDecember 18, 2025Sidley Secures Plan Confirmation in Prospect Medical Holdings' US$2.3 Billion Chapter 11 CaseDecember 17, 2025Sidley Represents Apollo Funds in Majority Investment in Prosol GroupDecember 16, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory